Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of GSK's SHR-1905?
SHR-1905 is a monoclonal antibody commercialized by GSK, with a leading Phase II program in Asthma. According to Globaldata, it...
Data Insights
SHR-1905 by GSK for Asthma: Likelihood of Approval
SHR-1905 is under clinical development by GSK and currently in Phase II for Asthma. According to GlobalData, Phase II drugs...